Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry.

Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry.

Item

http://www.wikidata.org/entity/Q33404151

Q33404151

about

Hemolytic uremic syndrome A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury Approaches to treatment of emerging Shiga toxin-producing Escherichia coli infections highlighting the O104:H4 serotype Haemolytic uraemic syndrome.Hemolytic uremic syndrome associated with Escherichia coli O157:H7 infection in older adults: a case report and review of the literature.Shiga toxin-producing Escherichia coli O104:H4: an emerging pathogen with enhanced virulence Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed.[Treatment of typical hemolytic-uremic syndrome. Knowledge gained from analyses of the 2011 E. coli outbreak].Multifaceted hemolytic uremic syndrome in pediatrics.Stability of relevant plasma protein activities in cryosupernatant plasma units during refrigerated storage for up to 5 days postthaw.Fatal hemolytic uremic syndrome associated with day care surgery and anaesthesia: a case report.Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome.New insights into Shiga toxin-mediated endothelial dysfunction in hemolytic uremic syndrome [Hemato-oncological diseases].Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab.Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement Direct acute tubular damage contributes to Shigatoxin-mediated kidney failure.Psychiatric symptoms in patients with Shiga toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome.Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.[Globosides as key players in the pathophysiology of Shiga toxin-associated acute kidney failure and Fabry disease].The efficacy of recombinant human soluble thrombomodulin for the treatment of shiga toxin-associated hemolytic uremic syndrome model mice.Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement.[After the crisis is before the crisis: Coping-strategies for public health emergency situations on different levels--experiences of the German E. coli outbreak 2011].Hypertension and mild chronic kidney disease persist following severe haemolytic uraemic syndrome caused by Shiga toxin-producing Escherichia coli O104:H4 in adults.Thrombocytopenia-Associated Multiple Organ Failure and Acute Kidney Injury.Ultrasound findings in EHEC-associated hemolytic-uremic syndrome and their clinical relevance.Involvement of Angiopoietin-2 and Tie2 Receptor Phosphorylation in STEC-HUS Mediated by Escherichia coli O104:H4 Pathology Consultation on the Diagnosis and Treatment of Thrombotic Microangiopathies (TMAs).Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury Pathophysiology of Pediatric Multiple Organ Dysfunction Syndrome.HUS and atypical HUS.Detection and Characterization of Shiga Toxin Producing Escherichia coli, Salmonella spp., and Yersinia Strains from Human, Animal, and Food Samples in San Luis, Argentina.Protective efficacy and pharmacokinetics of human/mouse chimeric anti-Stx1 and anti-Stx2 antibodies in mice.Complement involvement in kidney diseases: From physiopathology to therapeutical targeting The complement cascade and renal disease.Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome.Membrane versus centrifuge-based therapeutic plasma exchange: a randomized prospective crossover study.An emerging molecular understanding and novel targeted treatment approaches in pediatric kidney diseases.Biologic agents in the treatment of glomerulonephritides.Intermediate Follow-up of Pediatric Patients With Hemolytic Uremic Syndrome During the 2011 Outbreak Caused by E. coli O104:H4.

P2860

Q26799054-3F1A8B23-A23C-4235-872A-FC464603E34C Q26992169-5FD0AB93-9096-44EC-BCBA-A7E78508E8AA Q28087714-E19BE5C0-B305-429B-911B-1775FC7D675E Q30244707-09002F33-9F36-4088-9A7D-FF6C81E44D80 Q30249618-BAFE04FB-19C5-4482-B465-4D1F71CA5FBB Q30411012-3F9A2C83-736F-4748-9CBF-0383CDAF8087 Q33404149-11334A26-3D65-428C-8E89-613B49836EC2 Q33404545-8AFD5D6E-E605-4047-85F3-575159ACA91A Q33405452-B5FC948D-8241-4EF3-9A93-798BBC359605 Q33407886-AA7FC3F8-2E57-484C-B8C9-5D89F0FF92F2 Q33408687-965828DD-F0F3-49D3-A634-9D2B856663EF Q33409030-4CE9842F-96FA-4B72-8877-F29C5DFB0B6E Q33409878-EB25D3CD-6E96-40F2-B740-F53F64CDD6D2 Q33410075-E04B81AE-442F-43AB-B372-9C186129E1AD Q33411810-4872A34F-3662-45E8-999B-295BF3FC8B91 Q33413591-B81EDD07-8998-405C-B6E5-44FEEA1DD58E Q33415795-9B094482-D010-4010-A93C-DC424CB7AF55 Q33416354-9E30AC28-2781-4C00-A22A-DBC5431B0184 Q33417375-5F4BC422-2CC1-4456-B7BB-572E78C12437 Q33418419-7B7FC568-60FD-42F1-BDDD-47A07D9908D0 Q33420531-C6D5DC9A-0DF1-4EA7-9A65-F4BC7C4B39AA Q33423769-75345CC8-A0F4-4BFD-9304-6E4FA5F66D12 Q33424235-88ED6CC8-8D6F-478E-8F6B-A3ACBBFEF428 Q33424483-296F2723-E536-4ABC-BF92-B82B1D503AEA Q33426245-5E8F31F5-5303-4A0B-8D9F-422813F9BA64 Q33429127-73CC6855-2A2F-428C-8170-D4DFEE1D732D Q33429876-2D8B63AB-4BFA-458A-ADCF-DDD927F451D0 Q33431806-BD415C31-E583-48E8-9230-82EABC1E4498 Q33433630-0D34A4E4-0169-47F8-B064-1025118EF289 Q33439759-CD1623A9-CFA8-413A-B2D1-58F7FE73DC2E Q33441069-165B1F0B-F10E-429D-9B2F-46CA78D4B9FD Q34079853-9AE3270B-5702-4073-9B5F-3C4D3815F029 Q35221158-8733D35A-7BC6-48AF-9311-234656548B37 Q35567841-284F4DFD-0A35-4359-BC04-00007658097B Q37502706-0DBE507E-D646-4959-B709-FCA088D434AB Q37547496-9032AAD3-8A91-4A1B-959D-DDB1BE54C64B Q37714565-C5005BC3-94D0-4C6C-A446-70CA3B6A10C8 Q38232593-EE639B10-0C16-4220-AA96-BA821256C200 Q38514894-624781B5-F79E-4E65-83C2-EBDE2C8E87A6 Q38886279-C6C3BE1F-C630-40FC-9469-7DD6BD14D710

P2860

Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry.

Item

http://www.wikidata.org/entity/Q33404151

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu